Werth Family Investment Associates backs Likarda’s proprietary Kanslet™ diabetes treatment in dogs and cats.
KANSAS CITY, Kan. – Cutting-edge biotech research laboratory, Likarda, has received $4,000,000 in Series A funding from Werth Family Investment Associates, bringing the promise of future diabetes treatment options to dogs and cats.
Likarda is the leading regenerative medicine company for companion animals. They have discovered—and are commercializing—a better way to manage diabetes in dogs and cats. Their insulin-producing cell clusters, called the Kanslet™, can be infused into animals with diabetes. The process allows veterinarians to offer a minimally invasive, cost-effective answer to pet owners battling the burden of diabetes in dogs and cats.